SCHEMBL23975678

SCHEMBL23975678

Clc1nc2c(c(NCc3ccccn3)n1)CCC2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.55
BCHE P06276 2/20 0.55
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
ALOX15 P16050 1/20 0.51
JAK2 O60674 2/20 0.50
IGF1R P08069 1/20 0.50
PIM1 P11309 1/20 0.50
SRC P12931 1/20 0.50
CSNK2A2 P19784 1/20 0.50
KCNA5 P22460 1/20 0.50
JAK1 P23458 1/20 0.50
CCNE1 P24864 1/20 0.50
CDK2 P24941 1/20 0.50
TYK2 P29597 1/20 0.50
FLT4 P35916 1/20 0.50
FLT3 P36888 1/20 0.50
MAP3K8 P41279 1/20 0.50
CSNK1A1 P48729 1/20 0.50
GSK3B P49841 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30225331 1.00 ACHE (0.55) ACHEBCHECYP1A2CYP3A4ALOX15
SCHEMBL30225282 0.82 HIF1A (0.54) ACHEBCHECYP1A2CYP3A4ALOX15
SCHEMBL23975681 0.82 HIF1A (0.54) ACHEBCHECYP1A2CYP3A4ALOX15
SCHEMBL16838561 0.81 PDE5A (0.55) ACHEIGF1RKDM4EMEN1KMT2A
SCHEMBL2588501 0.79 VCP (0.56) ACHEBCHEKDM4EMEN1KMT2A
SCHEMBL17571943 0.77 CCNA2 (0.45) ACHEBCHECYP1A2CYP3A4IGF1R
SCHEMBL23976163 0.76 TDP1 (0.47) CYP1A2NPC1RAB9AKMT2AHPGD
SCHEMBL30225281 0.76 TDP1 (0.47) CYP1A2NPC1RAB9AKMT2AHPGD
SCHEMBL17926565 0.74 KMT2A (0.57) CYP1A2CYP3A4LMNAKDM4ENPC1
SCHEMBL18303570 0.74 LMNA (0.42) LMNAMEN1KMT2AMAOBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-07-20 US disclosed
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-07-20 US disclosed
US-20220396562-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2022-12-15 US disclosed
WO-2021222363-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2021-11-04 WO disclosed
WO-2021222483-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS SLC40A1, HAMP, SLC19A1 ACHE 4830/4885BCHE 3460/4885CYP1A2 1279/4885
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors HAMP, SLC40A1, FANCI ACHE 4876/4885BCHE 4033/4885CYP1A2 1830/4885
US-20220396562-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS HAMP, SLC40A1, FANCI ACHE 4876/4885BCHE 4033/4885CYP1A2 1830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.